Oxidative Stress Measured by Urine F2-Isoprostane Level is Associated With Prostate Cancer
Oxidative Stress Measured by Urine F2-Isoprostane Level is Associated With Prostate Cancer
复制标题
DOI：
10.1016/j.juro.2011.02.020
复制
发表时间：
2011-06-01
影响因子：
6.6
通讯作者：
Fowke, Jay H.
中科院分区：
文献类型：
--
作者：
Barocas, Daniel A.;Motley, Saundra;Fowke, Jay H.
目的：氧化应激与前列腺癌有多方面的关系。我们研究了F2-异前列腺素，一个有效的生物标志物的氧化应激，前列腺癌和高级别的前列腺上皮内瘤变的水平之间的关系。材料和方法：这种病例对照分析内的纳什维尔男性健康研究包括男性招募在前列腺活检。在活检前，从2,000多名男性中收集了身体形态测量、健康史和尿液。通过气相色谱/质谱法测量纳什维尔男性健康研究参与者的年龄匹配样本中的F2-异前列烷，所述参与者包括140名患有高度前列腺上皮内瘤形成的患者、160名活检阴性对照和200名前列腺癌病例。多变量线性和逻辑回归被用来确定F2-异前列腺素水平之间的关联，和高级别前列腺上皮内瘤变和前列腺癌cancer.Results：平均患者年龄为66.9岁（SD 7.2）和10.1%是非白人。前列腺癌患者校正的几何平均F2-异前列烷水平较高（1.82，95% CI 1.66-2.00）或高度前列腺上皮内瘤变（1.82，95%CI 1.68-1.96），但在Gleason评分中相似（p = 0.511）。高级别前列腺上皮内瘤变和前列腺癌的校正比值随着F2-异前列腺素四分位数的增加而增加（p趋势分别为0.015和0.047），最高F2-异前列烷四分位数与前列腺癌几率显著增加相关结论：前列腺上皮内瘤变和前列腺癌患者诊断前尿F2-异前列腺素水平升高，提示尿F2-异前列腺素可作为氧化应激在前列腺癌发生发展中作用的生物标志物。F2-异前列烷也可用于评估前列腺癌预防或治疗中靶向氧化应激机制的干预措施的功效。
Purpose: Oxidative stress is implicated in prostate cancer by several lines of evidence. We studied the relationship between the level of F2-isoprostanes, a validated biomarker of oxidative stress, and prostate cancer and high grade prostatic intraepithelial neoplasia.Materials and Methods: This case-control analysis within the Nashville Men's Health Study included men recruited at prostate biopsy. Body morphometrics, health history and urine were collected from more than 2,000 men before biopsy. F2-isoprostanes were measured by gas chromatography/mass spectrometry within an age matched sample of Nashville Men's Health Study participants that included 140 patients with high grade prostatic intraepithelial neoplasia, 160 biopsy negative controls and 200 prostate cancer cases. Multivariable linear and logistic regression was used to determine the associations between F2-isoprostane level, and high grade prostatic intraepithelial neoplasia and prostate cancer.Results: Mean patient age was 66.9 years (SD 7.2) and 10.1% were nonwhite. Adjusted geometric mean F2-isoprostane levels were higher in patients with prostate cancer (1.82, 95% CI 1.66-2.00) or high grade prostatic intraepithelial neoplasia (1.82, 95% CI 1.68-1.96) than in controls (1.63, 95% CI 1.49-1.78, p < 0.001), but were similar across Gleason scores (p = 0.511). The adjusted odds of high grade prostatic intraepithelial neoplasia and prostate cancer increased with increasing F2-isoprostane quartile (p-trend = 0.015 and 0.047, respectively) and the highest F2-isoprostane quartile was associated with significantly increased odds of prostate cancer (OR 2.44, 95% CI 1.17-5.09, p = 0.017).Conclusions: Pre-diagnosis urine F2-isoprostane level is increased in men with high grade prostatic intraepithelial neoplasia or prostate cancer, suggesting urinary F2-isoprostane provides a biomarker for the role for oxidative stress in prostate carcinogenesis. F2-isoprostanes may also serve to estimate the efficacy of interventions targeting oxidative stress mechanisms in prostate cancer prevention or treatment.